Why I’d snap up this FTSE 100 pharmaceutical provider alongside GlaxoSmithKline

I like GlaxoSmithKline plc (LON: GSK), but I also think today’s update from this smaller FTSE 100 (INDEXFTSE: UKX) competitor is encouraging.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

For years, big pharmaceutical companies such as GlaxoSmithKline and AstraZeneca have been struggling against an onslaught of generic competition. Me-too providers have swooped into previously profitable markets as soon as branded medicines time-out on patent protection.

Struggling to rebuild earnings

The situation has hit profits and cash flows hard for the major pharmaceutical companies, and they’re almost all struggling to rebuild earnings and growth by commercialising new formulations from their development pipelines, or by buying up smaller drug research and development outfits.

However, I like the generally cash-generating, defensive characteristics of the sector, which is fuelled by constant and predictable demand from customers needing medicines. So I’m still keen on the big pharmaceutical companies and their often quite large dividend yields.

However, I’m also keen to have a foot in the competition that has been causing the larger pharmaceutical firms so much financial pain, which is why I like FTSE 100 company Hikma Pharmaceuticals (LSE: HIK).

The company produces what it describes as “a broad range of branded and non-branded generic medicines,” which makes it one of big pharma’s antagonists!

The dividend has risen around 90% over the past five years and, with the share price close to 1,756p, the dividend yield runs close to 1.7%. That seems quite low, but earnings cover the payment around three and a half times, which suggests to me that the directors see plenty of opportunities to invest in growth going forward. Otherwise, they would probably pay more of the firm’s cash out in the dividend.

A positive update

Today’s trading update is positive. Chief executive Siggi Olafson said in the report the firm experienced “strong” growth in revenue and profitability last year. 2019 “is off to a good start.” The three divisions of Injectables, Generics and Branded are all making decent progress driven by a “broad product portfolio and recent product launches.”

I think the update is encouraging, but I’d be the first to admit the company’s record of trading has been a bit patchy at times, as you can see from this table:

Year to December

2013

2014

2015

2016

2017

2018

Revenue ($m)

1,365

1,489

1,440

1,950

1,936

2,076

Operating cash flow per share ($)

1.70

2.13

1.82

1.25

1.85

1.78

Normalised earnings per share ($)

1.47

1.57

1.45

1.46

0.99

1.91

Dividend per share ($)

0.20

0.22

0.32

0.33

0.34

0.38

Revenue has risen steadily, suggesting there has been no problem with sales. However, operating cash flow and earnings have been volatile, which could indicate the firm has had trouble squeezing profits from its operations.

Nevertheless, the directors kept the dividend growing over the past five years or so and things seem to be on track now. Today’s report talks about how the firm has been working hard to control costs. So it could be that inefficiencies crept into operations causing the profit wobbles of recent years, which is a challenge that most growing businesses face.

We’ll find out more from Hikma with the interim results for the six months to 30 June, due on 9 August.  

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any share mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Is now the time to buy BP shares? Here’s what the charts say

The best time to buy shares in a company is when they’re trading at a discount. But the future is…

Read more »

Investing Articles

Here’s how I’d use £50K to aim for a million when the stock market crashes

Seeing a stock market crash as a buying opportunity could prove lucrative for a well-prepared, long-term investor. Christopher Ruane explains…

Read more »

Stack of one pound coins falling over
Investing Articles

It’s up 27% with a P/E of 9! I’m considering the potential of this blossoming penny stock

Despite several years of losses, this UK penny stock has an impressive valuation. I’m looking to see if it could…

Read more »

US Stock

The Nvidia share price falls! Here’s what I think happens next for the S&P 500

Jon Smith reviews the overnight results from Nvidia and explains why this could stall the S&P 500 performance through to…

Read more »

Investing Articles

Down 15% today, is this FTSE 100 share too cheap for me to miss?

JD Sports' share price has tanked after the FTSE 100 share released another profit warning. Is this the opportunity I've…

Read more »

Investing Articles

Up 8% today, is this FTSE 100 growth stock a slam-dunk buy for me?

Halma's share price is soaring thanks to another headline-grabbing trading update. Is the FTSE 100 stock now too good for…

Read more »

Investing Articles

With a P/E ratio of just 10.5 is now a brilliant time to buy a cut-price FTSE 250 tracker?

Harvey Jones says a recent dip in the FTSE 250 leaves the index trading at bargain levels. One stock in…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

To build a passive income flow, I’d follow this Warren Buffett approach

Warren Buffett has set up passive income streams most people can only dream about. Our writer sees some practical lessons…

Read more »